Pharmacogenetics of Antiplatelet Therapy

Matteo Castrichini, Jasmine A. Luzum, Naveen Pereira

Research output: Contribution to journalReview articlepeer-review


Antiplatelet therapy is used in the treatment of patients with acute coronary syndromes, stroke, and those undergoing percutaneous coronary intervention. Clopidogrel is the most widely used antiplatelet P2Y12 inhibitor in clinical practice. Genetic variation in CYP2C19 may influence its enzymatic activity, resulting in individuals who are carriers of loss-of-function CYP2C19 alleles and thus have reduced active clopidogrel metabolites, high on-treatment platelet reactivity, and increased ischemic risk. Prospective studies have examined the utility of CYP2C19 genetic testing to guide antiplatelet therapy, and more recently published meta-analyses suggest that pharmacogenetics represents a key treatment strategy to individualize antiplatelet therapy. Rapid genetic tests, including bedside genotyping platforms that are validated and have high reproducibility, are available to guide selection of P2Y12 inhibitors in clinical practice. The aim of this review is to provide an overview of the background and rationale for the role of a guided antiplatelet approach to enhance patient care.

Original languageEnglish (US)
Pages (from-to)211-229
Number of pages19
JournalAnnual Review of Pharmacology and Toxicology
StatePublished - Jan 20 2023


  • CYP2C19
  • Guided antiplatelet therapy
  • dual antiplatelet therapy
  • pharmacogenetics
  • pharmacogenomics
  • precision medicine

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'Pharmacogenetics of Antiplatelet Therapy'. Together they form a unique fingerprint.

Cite this